West Pharmaceutical Services (WST) Price to Earnings (2009 - 2026)

West Pharmaceutical Services has disclosed Price to Earnings across 18 years of filings, most recently posting 170.88 for Q2 2026.

• In Q2 2026, Price to Earnings rose 37.73% year-over-year to 170.88; the TTM figure through Jun 2026 stood at 46.0 (up 38.43% YoY), while the FY2025 annual figure was 41.33, down 16.58% from the prior year.
• Price to Earnings came in at 170.88 for Q2 2026 at West Pharmaceutical Services, up from 131.24 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 260.24 in Q1 2024 to a low of 122.27 in Q2 2022.
• Average Price to Earnings over 5 years is 173.54, with a median of 175.46 recorded in 2022.
• Year-over-year, Price to Earnings soared 54.01% in 2023 and sank 44.59% in 2025.
• Over 5 years, Price to Earnings stood at 174.74 in 2022, then grew by 10.78% to 193.57 in 2023, then fell by 4.49% to 184.88 in 2024, then fell by 16.42% to 154.52 in 2025, then climbed by 10.59% to 170.88 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 170.88 in Q2 2026, 131.24 in Q1 2026, and 154.52 in Q4 2025.